APCCC 2024: Management of Frail Patients with mHSPC
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Management of Frail Patients with mHSPC, M1 disease, abiraterone, prednisolone, abiraterone plus prednisolone, androgen deprivation therapy (ADT), enzalutamide, apalutamide, darolutamide, LHRH antagonists, androgen receptor pathway inhibitor (ARPI).